New insights into breast cancer ecosystem: The complex crosstalk between exosomes and metabolic reprogramming offers promising therapeutic prospects
Peer-Reviewed Publication
Updates every hour. Last Updated: 14-Aug-2025 22:11 ET (15-Aug-2025 02:11 GMT/UTC)
Breast cancer progression is driven by a complex ecosystem where cancer cells and their microenvironment communicate extensively. A recent Perspective article in Science Bulletin from a team led by Dr. Wenqian Wang (The Second Affiliated Hospital of Wenzhou Medical University), Professor Min Wu (University of Chinese Academy of Sciences, Wenzhou Institute), and Associate Professor Chunyan Hua (Wenzhou Medical University) reveals the crucial crosstalk between exosomes—small messengers released by cells—and metabolic reprogramming in breast cancer. This interaction influences tumor growth, resistance to therapy, and cancer stem cell survival. The study proposes innovative diagnostic and therapeutic strategies targeting this “exosome-metabolism axis”, offering new hope for more effective patient management.
Researchers at the University of Chicago have developed a more sensitive liquid biopsy test that uses RNA instead of DNA for detecting cancer. Using blood samples from patients with colorectal cancer, the test was able to detect the earliest stages of the disease with 95% accuracy, vastly improving on current, commercially available, non-invasive testing methods.
China’s “double reduction” policy, launched in 2021, seeks to ease student stress by limiting homework and curbing off-campus tutoring. Early results show reduced anxiety and greater parent satisfaction, yet challenges remain. Teacher workloads have increased, resource gaps persist in rural schools, and underground tutoring continues. Sustained progress will require systemic reforms and collaboration among schools, families, and policymakers to ensure balanced, high-quality education for all.
An international research team led by CIC bioGUNE has advanced understanding of classical homocystinuria, a rare genetic disorder that impairs the breakdown of homocysteine, causing systemic health issues. Published in The FEBS Journal, the study focuses on the R336C mutation in the CBS enzyme. Contrary to previous beliefs that this mutation denatures the enzyme, researchers found that the enzyme's structure remains mostly intact but exhibits abnormal flexibility. This impairs communication between its cofactor (vitamin B6 derivative) and catalytic site, reducing enzymatic function.
Key findings include:
The R336C mutation causes subtle structural shifts affecting the PLP cofactor’s function.
It disrupts enzyme activity not by structural collapse but by altering its internal dynamics.
The Bateman module, crucial for enzyme regulation, becomes overly mobile, hindering substrate access.
These insights explain poor patient response to vitamin B6 therapy and suggest new treatment strategies, such as drugs to restore cofactor interaction or modulate enzyme flexibility. The study emphasizes the value of international collaboration in rare disease research and the development of personalized medicine.
University of Cagliari researcher Dr. Mirko Manchia discusses his pioneering work uncovering genetic factors behind lithium response in bipolar disorder. His Genomic Press Interview reveals how personal experiences shaped a career dedicated to understanding why medications work differently across patients, offering hope for personalized psychiatric treatment approaches.